tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

BEAM Stock Latest News

Beam Therapeutics Receives Buy Rating on Promising Sickle Cell Therapy Data and Market Potential
RatingsBeam Therapeutics Receives Buy Rating on Promising Sickle Cell Therapy Data and Market Potential
1d ago
BEAM
Bullish Outlook on Beam Therapeutics Driven by Promising Clinical Data and Market Opportunities
PremiumRatings
Bullish Outlook on Beam Therapeutics Driven by Promising Clinical Data and Market Opportunities
2d ago
BEAM
Positive Outlook for Beam Therapeutics’ BEAM-101 in Sickle Cell Disease Treatment Justifies Buy Rating
PremiumRatings
Positive Outlook for Beam Therapeutics’ BEAM-101 in Sickle Cell Disease Treatment Justifies Buy Rating
2d ago
BEAM
Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease, Justifying Buy Rating
PremiumRatings
Beam Therapeutics’ BEAM-101 Shows Promising Results in Sickle Cell Disease, Justifying Buy Rating
3d ago
BEAM
Beam Therapeutics’ BEAM-101: Promising Advancements in Sickle Cell Disease Treatment with Strong Phase 1/2 Trial Results
PremiumRatings
Beam Therapeutics’ BEAM-101: Promising Advancements in Sickle Cell Disease Treatment with Strong Phase 1/2 Trial Results
5d ago
BEAM
Beam Therapeutics announces new data from BEACON Phase 1/2 trial
PremiumThe FlyBeam Therapeutics announces new data from BEACON Phase 1/2 trial
5d ago
BEAM
Cathie Wood’s ARK Investment buys 349K shares of Beam Therapeutics today
Premium
The Fly
Cathie Wood’s ARK Investment buys 349K shares of Beam Therapeutics today
7d ago
BEAM
Beam Therapeutics Confirms Key Decisions at Annual Meeting
Premium
Company Announcements
Beam Therapeutics Confirms Key Decisions at Annual Meeting
12d ago
8K
BEAM
Beam Therapeutics announces U.S. FDA granted ODD to BEAM-101
PremiumThe Fly
Beam Therapeutics announces U.S. FDA granted ODD to BEAM-101
15d ago
BEAM
Beam Therapeutics treatment of sickle cell disease granted orphan designation
PremiumThe Fly
Beam Therapeutics treatment of sickle cell disease granted orphan designation
19d ago
BEAM
Beam Therapeutics receives orphan drug designation for BEAM-302
PremiumThe Fly
Beam Therapeutics receives orphan drug designation for BEAM-302
20d ago
BEAM
Beam Therapeutics treatment of alpha-1 antitrypsin deficiency gets orphan status
PremiumThe Fly
Beam Therapeutics treatment of alpha-1 antitrypsin deficiency gets orphan status
21d ago
BEAM
Beam Therapeutics announces FDA grants RMAT designation to BEAM-302
PremiumThe FlyBeam Therapeutics announces FDA grants RMAT designation to BEAM-302
1M ago
BEAM
Beam Therapeutics: Promising Gene Editing Advancements and Strategic Execution Reinforce Buy Rating
Premium
Ratings
Beam Therapeutics: Promising Gene Editing Advancements and Strategic Execution Reinforce Buy Rating
1M ago
BEAM
Beam Therapeutics: Promising Pipeline and Financial Stability Justify Buy Rating
Premium
Ratings
Beam Therapeutics: Promising Pipeline and Financial Stability Justify Buy Rating
1M ago
BEAM
Beam Therapeutics: Promising Advancements in Base Editing and Strong Financial Position Support Buy Rating
PremiumRatings
Beam Therapeutics: Promising Advancements in Base Editing and Strong Financial Position Support Buy Rating
1M ago
BEAM
Beam Therapeutics price target lowered to $55 from $78 at Guggenheim
PremiumThe Fly
Beam Therapeutics price target lowered to $55 from $78 at Guggenheim
1M ago
BEAM
VRTX
Beam Therapeutics price target lowered to $70 from $75 at Wells Fargo
PremiumThe Fly
Beam Therapeutics price target lowered to $70 from $75 at Wells Fargo
1M ago
BEAM
Beam Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
PremiumRatings
Beam Therapeutics: Promising Developments and Strong Financial Position Justify Buy Rating
1M ago
BEAM
Beam Therapeutics: Promising Growth Prospects and Strategic Advancements Support Buy Rating
PremiumRatingsBeam Therapeutics: Promising Growth Prospects and Strategic Advancements Support Buy Rating
1M ago
BEAM
Beam Therapeutics price target lowered to $25 from $31 at Barclays
Premium
The Fly
Beam Therapeutics price target lowered to $25 from $31 at Barclays
1M ago
BEAM
Beam Therapeutics Reports Strong Q1 2025 Progress
Premium
Company Announcements
Beam Therapeutics Reports Strong Q1 2025 Progress
1M ago
BEAM

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >